{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:44:35Z","timestamp":1781826275119,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"crossref","award":["HSRI. 59-005"],"award-info":[{"award-number":["HSRI. 59-005"]}],"id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"crossref","award":["RTA 5980011"],"award-info":[{"award-number":["RTA 5980011"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Royal Golden Jubilee Ph.D. Program","award":["PHD\/0180\/2554"],"award-info":[{"award-number":["PHD\/0180\/2554"]}]},{"name":"The Royal Golden Jubilee Ph.D. Program","award":["PHD\/0180\/2554"],"award-info":[{"award-number":["PHD\/0180\/2554"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12886-019-1086-1","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T05:48:41Z","timestamp":1553838521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand"],"prefix":"10.1186","volume":"19","author":[{"given":"Suthasinee","family":"Kumluang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6177-1587","authenticated-orcid":false,"given":"Lily","family":"Ingsrisawang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermsiri","family":"Sangroongruangsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usa","family":"Chaikledkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanapat","family":"Ratanapakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paisan","family":"Ruamviboonsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wongsiri","family":"Taweebanjongsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janejit","family":"Choovuthayakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somanus","family":"Thoongsuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prut","family":"Hanutsaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittisak","family":"Kulvichit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitiporn","family":"Ratanapojnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warapat","family":"Wongsawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattara","family":"Leelahavarong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yot","family":"Teerawattananon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,29]]},"reference":[{"issue":"2","key":"1086_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313\u20139.","journal-title":"Ophthalmology."},{"issue":"3","key":"1086_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556\u201364.","journal-title":"Diabetes Care"},{"issue":"7","key":"1086_CR3","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259\u201373.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1086_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1155\/2015\/138070","volume":"2015","author":"M Ishikawa","year":"2015","unstructured":"Ishikawa M, Jin D, Sawada Y, Abe S, Yoshitomi T. Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:10.","journal-title":"J Ophthalmol"},{"issue":"2","key":"1086_CR5","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"1086_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s11892-012-0283-6","volume":"12","author":"J Ding","year":"2012","unstructured":"Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Current Diabetes Reports. 2012;12(4):346\u201354.","journal-title":"Current Diabetes Reports"},{"issue":"4","key":"1086_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ceo.12696","volume":"44","author":"DSW Ting","year":"2016","unstructured":"Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44(4):260\u201377.","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"1086_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3109\/09286586.2010.545502","volume":"18","author":"W Jenchitr","year":"2011","unstructured":"Jenchitr W, Ruamviboonsuk P, Sanmee A, Pokawattana N. Prevalence of age-related macular degeneration in Thailand. Ophthalmic Epidemiol. 2011;18(1):48\u201352.","journal-title":"Ophthalmic Epidemiol"},{"key":"1086_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/CEOR.S37458","volume":"4","author":"T Anothaisintawee","year":"2012","unstructured":"Anothaisintawee T, Leelahavarong P, Ratanapakorn T, Teerawattananon Y. The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand\u2019s pharmaceutical benefit package. ClinicoEconomics and Outcomes Research. 2012;4:361\u201374.","journal-title":"ClinicoEconomics and Outcomes Research"},{"issue":"14","key":"1086_CR10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus Verteporfin for Neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"1086_CR11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"key":"1086_CR12","doi-asserted-by":"crossref","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst. Rev. 2014;8.","DOI":"10.1002\/14651858.CD005139.pub3"},{"key":"1086_CR13","doi-asserted-by":"crossref","unstructured":"Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst. Rev. 2014;(10):Cd007419.","DOI":"10.1002\/14651858.CD007419.pub4"},{"key":"1086_CR14","doi-asserted-by":"crossref","unstructured":"Ford JA, Elders A, Shyangdan D, Royle P, Waugh N. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ. 2012;345.","DOI":"10.1136\/bmj.e5182"},{"issue":"8","key":"1086_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042701","volume":"7","author":"C Schmucker","year":"2012","unstructured":"Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. A safety review and meta-analyses of bevacizumab and Ranibizumab: off-label versus Goldstandard. PLoS One. 2012;7(8):e42701.","journal-title":"PLoS One"},{"issue":"8","key":"1086_CR16","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/IAE.0b013e3182278ab4","volume":"31","author":"MI Reis van der","year":"2011","unstructured":"van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina. 2011;31(8):1449\u201369.","journal-title":"Retina"},{"issue":"9","key":"1086_CR17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/heapol\/czu120","volume":"30","author":"V Tangcharoensathien","year":"2015","unstructured":"Tangcharoensathien V, Limwattananon S, Patcharanarumol W, Thammatacharee J, Jongudomsuk P, Sirilak S. Achieving universal health coverage goals in Thailand: the vital role of strategic purchasing. Health Policy Plan. 2015;30(9):1152\u201361.","journal-title":"Health Policy Plan"},{"issue":"1","key":"1086_CR18","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1186\/s40064-016-3665-4","volume":"5","author":"SC Paek","year":"2016","unstructured":"Paek SC, Meemon N, Wan TTH. Thailand\u2019s universal coverage scheme and its impact on health-seeking behavior. SpringerPlus. 2016;5(1):1952.","journal-title":"SpringerPlus"},{"issue":"4","key":"1086_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195179","volume":"13","author":"W Patcharanarumol","year":"2018","unstructured":"Patcharanarumol W, Panichkriangkrai W, Sommanuttaweechai A, Hanson K, Wanwong Y, Tangcharoensathien V. Strategic purchasing and health system efficiency: a comparison of two financing schemes in Thailand. PLoS One. 2018;13(4):e0195179.","journal-title":"PLoS One"},{"issue":"9","key":"1086_CR20","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40261-018-0678-5","volume":"38","author":"S Sangroongruangsri","year":"2018","unstructured":"Sangroongruangsri S, Chaikledkaew U, Kumluang S, Wu O, Geue C, Ratanapakorn T, et al. Real-world safety of intravitreal bevacizumab and Ranibizumab treatments for retinal diseases in Thailand: a prospective observational study. Clin. Drug Investig. 2018;38(9):853\u201365.","journal-title":"Clin. Drug Investig"},{"key":"1086_CR21","volume-title":"Summary benchmarks for preferred practice pattern guidelines: Thai translation (in Thai)","author":"The Royal College of Ophthalmology of Thailand","year":"2013","unstructured":"The Royal College of Ophthalmology of Thailand. Summary benchmarks for preferred practice pattern guidelines: Thai translation (in Thai). San Francisco: American Academy of Ophthalmology; 2013. \n                    https:\/\/www.aao.org\/Assets\/480a5654-b6a2-449e-8e54-aac93498df19\/635116445677530000\/thai-summary-benchmarks-2013-pdf\n                    \n                  . Accessed 17 Aug 2016."},{"key":"1086_CR22","unstructured":"Working Group for the outline criteria use and monitoring on E2 category under the Sub-committee for development of the NLEM. The outline criteria use and monitoring on E2 category: bevacizumab for nAMD and DME (in Thai). Nonthaburi, Thailand: Ministry of public health, Thailand; 2015. \n                    http:\/\/www.fda.moph.go.th\/sites\/drug\/Shared%20Documents\/National-Drug-Policy\/04\/01\/17%20Bevacizumab%20AMD_DME%20Guide_2559.pdf\n                    \n                  . Accessed 18 Sept 2017."},{"key":"1086_CR23","unstructured":"Bureau of Medicines Medical Supplies and Vaccines Management. Pre-authorization form: Bevacizumab for Wet form of subfoveal, juxtafoveal choroidal neovascularization (CNV) due-to aged related macular degeneration and Diabetic Macular Edema (DME). 2015 2 Oct 2018. \n                    http:\/\/drugfund.nhso.go.th\/drugfund\/webfiles\/images\/26112015032819-18BevacizumabAMD_DMEGuide_2015.pdf\n                    \n                  . Accessed 2 Oct 2018."},{"issue":"20","key":"1086_CR24","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"The CATT Research Group","year":"2011","unstructured":"The CATT Research Group. Ranibizumab and bevacizumab for Neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908.","journal-title":"N Engl J Med"},{"issue":"9900","key":"1086_CR25","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258\u201367.","journal-title":"Lancet"},{"issue":"7","key":"1086_CR26","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046\u201350.","journal-title":"Retina"},{"issue":"3","key":"1086_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"3","key":"1086_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/aje\/kwg115","volume":"158","author":"MS Cepeda","year":"2003","unstructured":"Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol. 2003;158(3):280\u20137.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"1086_CR29","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, G-s Y, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of Neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388\u201398.","journal-title":"Ophthalmology"},{"issue":"1","key":"1086_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0974-9233.173133","volume":"23","author":"A Agarwal","year":"2016","unstructured":"Agarwal A, Aggarwal K, Gupta V. Management of neovascular age-related macular degeneration: a review on landmark randomized controlled trials. Middle East Afr J Ophthalmol. 2016;23(1):27\u201337.","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"5","key":"1086_CR31","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","unstructured":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121(5):1092\u2013101.","journal-title":"Ophthalmology"},{"issue":"12","key":"1086_CR32","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","volume":"122","author":"GS Ying","year":"2015","unstructured":"Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, et al. Association of Baseline Characteristics and Early Vision Response with 2-year vision outcomes in the comparison of AMD treatments trials (CATT). Ophthalmology. 2015;122(12):2523\u201331 e1.","journal-title":"Ophthalmology"},{"issue":"8","key":"1086_CR33","first-page":"790","volume":"98","author":"R Khotcharrat","year":"2015","unstructured":"Khotcharrat R, Patikulsila D, Hanutsaha P, Khiaocham U, Ratanapakorn T, Sutheerawatananonda M, et al. Epidemiology of age-related macular degeneration among the elderly population in Thailand. J Med Assoc Thail. 2015;98(8):790\u20137.","journal-title":"J Med Assoc Thail"},{"issue":"11","key":"1086_CR34","first-page":"1483","volume":"96","author":"P Kunavisarut","year":"2013","unstructured":"Kunavisarut P, Saenpen N, Ittipunkul N, Patikulsila D, Choovuthayakorn J, Watanachai N, et al. The use of intravitreal anti-vascular endothelial growth factor injection and its complications in Chiang Mai University Hospital. J Med Assoc Thail. 2013;96(11):1483\u201390.","journal-title":"J Med Assoc Thail"},{"issue":"1","key":"1086_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragad\u00f3ttir R. Comparison of Ranibizumab and bevacizumab for Neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146\u201352.","journal-title":"Ophthalmology"},{"issue":"6","key":"1086_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","volume":"28","author":"S Cai","year":"2017","unstructured":"Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol. 2017;28(6):636\u201343.","journal-title":"Curr Opin Ophthalmol"},{"key":"1086_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajo.2018.04.010","volume":"191","author":"NM Holekamp","year":"2018","unstructured":"Holekamp NM, Campbell J, Almony A, Ingraham H, Marks S, Chandwani H, et al. Vision outcomes following anti-vascular endothelial growth factor treatment of diabetic macular edema in clinical practice. Am J Ophthalmol. 2018;191:83\u201391.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"1086_CR38","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","volume":"120","author":"L Kodjikian","year":"2013","unstructured":"Kodjikian L, Souied EH, Mimoun G, Mauget-Fa\u00ffsse M, Behar-Cohen F, Decullier E, et al. Ranibizumab versus bevacizumab for Neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120(11):2300\u20139.","journal-title":"Ophthalmology."},{"key":"1086_CR39","first-page":"311","volume":"107","author":"PK Kaiser","year":"2009","unstructured":"Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (an AOS thesis). Trans Am Ophthalmol Soc. 2009;107:311\u201324.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"4","key":"1086_CR40","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0002-9394(03)00388-X","volume":"136","author":"SA Cotter","year":"2003","unstructured":"Cotter SA, Chu RH, Chandler DL, Beck RW, Holmes JM, Rice ML, et al. Reliability of the electronic early treatment diabetic retinopathy study testing protocol in children 7 to <13 years old. Am J Ophthalmol. 2003;136(4):655\u201361.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1086_CR41","first-page":"82","volume":"2","author":"S Kalpana","year":"2013","unstructured":"Kalpana S, Karthick J, Jayarajini S. Comparison of static visual acuity between Snellen and early treatment diabetic retinopathy study charts. Int. J. Educ Res. Dev. 2013;2(3):82\u20138.","journal-title":"Int. J. Educ Res. Dev"},{"issue":"13","key":"1086_CR42","first-page":"3951","volume":"55","author":"N Cvetkova","year":"2014","unstructured":"Cvetkova N, Maerker D, Helbig H, Hoelldobler K. Ranibizumab (Lucentis) in neovascular age- related macular degeneration (AMD): five year follow up. Invest Ophthalmol Vis Sci. 2014;55(13):3951.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1086_CR43","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ajo.2014.05.014","volume":"158","author":"EM Lad","year":"2014","unstructured":"Lad EM, Hammill BG, Qualls LG, Wang F, Cousins SW, Curtis LH. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. Am J. Ophthalmol. 2014;158(3):537\u201343.e2.","journal-title":"Am J. Ophthalmol"},{"issue":"4","key":"1086_CR44","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00417-013-2562-6","volume":"252","author":"A Wolf","year":"2014","unstructured":"Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):647\u201355.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"1086_CR45","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1097\/IAE.0000000000000548","volume":"35","author":"EH Souied","year":"2015","unstructured":"Souied EH, Oubraham H, Mimoun G, Cohen SY, Quere S, Derveloy A. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the twin study. Retina. 2015;35(9):1743\u20139.","journal-title":"Retina"},{"key":"1086_CR46","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016;100:1623\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1086_CR47","doi-asserted-by":"publisher","first-page":"4367631","DOI":"10.1155\/2016\/4367631","volume":"2016","author":"MK Tsilimbaris","year":"2016","unstructured":"Tsilimbaris MK, Lopez-Galvez MI, Gallego-Pinazo R, Margaron P, Lambrou GN. Epidemiological and clinical baseline characteristics as predictive biomarkers of response to anti-VEGF treatment in patients with Neovascular AMD. J Ophthalmol. 2016;2016:4367631.","journal-title":"J Ophthalmol"},{"issue":"2","key":"1086_CR48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","volume":"114","author":"DS Boyer","year":"2007","unstructured":"Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246\u201352.","journal-title":"Ophthalmology"},{"issue":"6","key":"1086_CR49","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","volume":"144","author":"PK Kaiser","year":"2007","unstructured":"Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144(6):850\u20137.","journal-title":"Am J Ophthalmol"},{"key":"1086_CR50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1155\/2012\/690641","volume":"2012","author":"SM Hariprasad","year":"2012","unstructured":"Hariprasad SM, Morse LS, Shapiro H, Wong P, Tuomi L. Fixed monthly versus less frequent Ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration. J Ophthalmol. 2012;2012:8.","journal-title":"J Ophthalmol"},{"issue":"1","key":"1086_CR51","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","volume":"120","author":"GS Ying","year":"2013","unstructured":"Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):122\u20139.","journal-title":"Ophthalmology"},{"issue":"6","key":"1086_CR52","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2016;123(6):1351\u20139.","journal-title":"Ophthalmology"},{"key":"1086_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1155\/2013\/676049","volume":"2013","author":"K Fang","year":"2013","unstructured":"Fang K, Tian J, Qing X, Li S, Hou J, Li J, et al. Predictors of visual response to intravitreal bevacizumab for treatment of Neovascular age-related macular degeneration. J Ophthalmol. 2013;2013:9.","journal-title":"J Ophthalmol"},{"key":"1086_CR54","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/bjo.2008.141879","volume":"93","author":"RP Singh","year":"2009","unstructured":"Singh RP, Fu EX, Smith SD, Williams DR, Kaiser PK. Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study. Br J Ophthalmol. 2009;93:1353\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"1086_CR55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10792-008-9243-1","volume":"29","author":"J Levy","year":"2008","unstructured":"Levy J, Shneck M, Rosen S, Klemperer I, Rand D, Weinstein O, et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol. 2008;29(5):349.","journal-title":"Int Ophthalmol"},{"issue":"8","key":"1086_CR56","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1097\/IAE.0b013e3182475aea","volume":"32","author":"J Chhablani","year":"2012","unstructured":"Chhablani J, Kozak IR, Mojana F, Cheng L, Morrison VL, Wang H, et al. Fundus autofluorescence not predictive of treatment response to intravitreal bevacizumab in exudative age-related macular degeneration. Retina. 2012;32(8):1465\u201370.","journal-title":"Retina"},{"key":"1086_CR57","unstructured":"The Drug And Medical Supply Information Center. Reference Price database: BEVACIZUMAB VIAL 100 MG \/4ML (4 ML). Nonthaburi, Thailand: Ministry of Public Health; 2017. \n                    http:\/\/dmsic.moph.go.th\/dmsic\/index.php?p=1&type=3&s=3&id=drug_normal&keyword=b&sh=1&sid=BEVACIZUMAB%20VIAL%20100%20MG%20\/4ML%20(4%20ML)\n                    \n                  . Accessed 5 July 2017."},{"key":"1086_CR58","unstructured":"The Drug And Medical Supply Information Center. Reference Price Database: RANIBIZUMAB VIAL 10 MG \/ML (0.23 ML). Nonthaburi, Thailand: Ministry of Public Health; 2017. \n                    http:\/\/dmsic.moph.go.th\/dmsic\/index.php?p=1&type=3&s=3&id=drug_normal&keyword=r&sh=1&sid=RANIBIZUMAB%20VIAL%2010%20MG%20\/ML%20(0.23%20ML)\n                    \n                  . Accessed 18 Sept 2017."},{"key":"1086_CR59","unstructured":"Rates of Exchange of Commercial Banks in Bangkok Metropolis (2002-present). Bank of Thailand; 2017. \n                    http:\/\/www2.bot.or.th\/statistics\/ReportPage.aspx?reportID=123&language=eng\n                    \n                  . Accessed 28 Dec 2017."},{"key":"1086_CR60","unstructured":"World Health Organization. The selection and use of essential medicines. Report of the WHO Expert Committee, 2015 (including the 19th WHO Model List of Essential Medicines and the 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization2015 (WHO Technical Report Series, No. 994). \n                    https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/189763\/9789241209946_eng.pdf;jsessionid=C35F0747D258F60EA882499660BCC8A0?sequence=1\n                    \n                  . Accessed 6 July 2017."},{"key":"1086_CR61","unstructured":"National Health Security Office. NHSO annual report 2016. National Health Security Office: Bangkok; 2017. \n                    http:\/\/www.nhso.go.th\/frontend\/page-about_result.aspx\n                    \n                  . Accessed 5 July 2017."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1086-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1086-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1086-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:11:00Z","timestamp":1585354260000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1086-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,29]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1086"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1086-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,29]]},"assertion":[{"value":"27 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was approved by the Institute for the Development of Human Research Protections, Ministry of Public Health, Thailand (IHRP.32\/2012), the Thai Clinical Trials Registry (TCTR20141002001), and the institutional review board of each hospital. All patients were enrolled into the study after providing written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prut Hanutsaha has received an honorarium and travel support from Novartis to attend a scientific meeting. Wongsiri Taweebanjongsin has received an honorarium from Novartis, a travel support to meeting from TRB Chemedica, and payment for lectures from Novartis and Bayer. Other authors declare that they have no competing interests which are directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"82"}}